Who
Ellen Feigal
Director
Company insider
Files Form 4 as: Director, NextCure; Director, Xencor.
In numbers
- Trades disclosed
- 27
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $258K
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 7 Nov 2018
- Last trade
- 18 Jun 2026
- Last filed
- 8 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 22 Jun 2026 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,340 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,340 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $89K6,843 at $13.06 | filing |
| 18 Jun 2026filed 22 Jun 2026 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $89K6,843 at $13.06 | filing |
| 16 Jun 2026filed 8 Jul 2026 | XNCR XencorBiotechnology | SEC FORM 4 Code A | —10,302 at $0.00 | filing |
| 16 Jun 2026filed 8 Jul 2026 | XNCR Xencoroption or derivative · Biotechnology | SEC FORM 4 Code A | —20,604 at $0.00 | filing |
| 16 Jun 2026filed 8 Jul 2026 | XNCR Xencoroption or derivative · Biotechnology | SEC FORM 4 Code A | —20,604 at $0.00 | filing |
| 16 Jun 2026filed 8 Jul 2026 | XNCR XencorBiotechnology | SEC FORM 4 Code A | —10,302 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,700 at $0.00 | filing |
| 16 Jun 2025filed 16 Jun 2025 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $28K2,993 at $9.22 | filing |
| 12 Jun 2025filed 16 Jun 2025 | XNCR Xencoroption or derivative · Biotechnology | SEC FORM 4 Code A | —27,372 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | XNCR XencorBiotechnology | SEC FORM 4 Code A | —13,686 at $0.00 | filing |
| 27 Sep 2024filed 1 Oct 2024 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $52K2,503 at $20.68 | filing |
| 20 Jun 2024filed 21 Jun 2024 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,700 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | XNCR Xencoroption or derivative · Biotechnology | SEC FORM 4 Code A | —11,971 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | XNCR XencorBiotechnology | SEC FORM 4 Code A | —5,986 at $0.00 | filing |
| 22 Jun 2023filed 23 Jun 2023 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,250 at $0.00 | filing |
| 20 Jun 2023filed 22 Jun 2023 | XNCR Xencoroption or derivative · Biotechnology | SEC FORM 4 Code A | —10,013 at $0.00 | filing |
| 20 Jun 2023filed 22 Jun 2023 | XNCR XencorBiotechnology | SEC FORM 4 Code A | —5,007 at $0.00 | filing |
| 23 Jun 2022filed 27 Jun 2022 | XNCR Xencoroption or derivative · Biotechnology | SEC FORM 4 Code A | —21,412 at $0.00 | filing |
News
Analyzing Cardiff Oncology (NASDAQ:CRDF) and Xencor (NASDAQ:XNCR)XNCR · themarketsdaily.com · 21 Oct 2026
0 headlines in the last 90 days name Ellen Feigal; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.